Bapineuzumab Failure Could Mean Bleak Outlook for Alzheimer’s Drugs

Pfizer, Johnson & Johnson (J&J) and Elan’s termination of their late-stage program for investigational Alzheimer’s drug bapineuzumab following the second failed study may not negatively impact the companies but could foreshadow a bleak outlook for the future of Alzheimer’s drug development, analysts say. Bapineuzumab missed its co-primary endpoints, failing to improve cognitive and functional performance compared with placebo in Study 302, its second of four Phase III studies to report data, the companies said.
Washington Drug Letter